A board to discuss future MS therapies in early stage (Phase I or II) trials.


Postby bromley » Wed Nov 01, 2006 1:21 am

It's EAE / animal model so don't get excited.

Methylthioadenosine Effective in Animal Models of Multiple Sclerosis 01 November 2006

Methylthioadenosine (MTA), an adenine nucleoside produced from S-adenosylmethionine, is effective in animal models of acute and chronic multiple sclerosis (MS), according to a report in the September issue of the Annals of Neurology.

"A cell compound such as methylthioadenosine is able to modulate the immune response, and it might become a useful therapy for autoimmune diseases with less toxicity than other drugs because the cell has several mechanisms to compensate its excess," Dr. Pablo Villoslada told Reuters Health.

Dr. Villoslada and colleagues from the University of Navarra, Spain studied the effects of intraperitoneal MTA in rodent experimental autoimmune encephalomyelitis (EAE, a model of MS) and in peripheral blood mononuclear cells from multiple sclerosis patients and healthy controls.

In the acute model, the authors report, MTA on the same day as induction of EAE prevented acute encephalomyelitis in 5 of 10 Lewis rats, whereas 9 of 10 placebo-treated animals developed neurological symptoms of acute EAE.

In rats with ongoing chronic-relapsing EAE, MTA also improved histological findings and decreased the rate of second relapse, the results indicate.

MTA treatment significantly attenuated the proliferative response of rat splenocytes to myelin basic protein and phytohemagglutinin, the researchers note, and had similar immunomodulatory effects on peripheral blood mononuclear cells from rats and from patients with MS.

"MTA would be an excellent candidate drug to be tested in patients with MS because it is safe and is effective in preventing brain autoimmune attack," the authors conclude.

"In addition," they write, "because MTA may have a pleiotropic mechanism of action in preventing T-cell activation, which is a critical step in autoimmune diseases, but without inducing immunosuppression, it appears an ideal candidate for combining with other immunomodulatory drugs to obtain a higher efficacy in stopping relapses and disease progression without increasing side effects."

Because the mechanism of action is immunomodulation by preventing T cell activation, "our target will be other autoimmune diseases and transplant rejection," Dr. Villoslada added. "We have preliminary data suggesting positive effects in type 1 diabetes and rheumatoid arthritis animal models."

Source: Ann Neurol 2006;60:323-334.
User avatar
Family Elder
Posts: 1888
Joined: Fri Sep 10, 2004 3:00 pm


Re: Methylthioadenosine

Postby CureOrBust » Wed Nov 01, 2006 1:34 am

bromley wrote:It's EAE / animal model so don't get excited.

Methylthioadenosine beneficial in multiple sclerosis too bad we cant get to the actual full text
User avatar
Family Elder
Posts: 3341
Joined: Wed Jul 27, 2005 3:00 pm
Location: Sydney, Australia

Postby bromley » Wed Nov 01, 2006 1:59 am

Approximately 40% of patients, however, fail to respond to current immunomodulatory treatments and progress to major brain damage and disability.

Not something I wanted to read at 9am

User avatar
Family Elder
Posts: 1888
Joined: Fri Sep 10, 2004 3:00 pm

Postby viper498 » Wed Nov 01, 2006 7:11 am

No Kidding!!!!
User avatar
Family Elder
Posts: 428
Joined: Sun Oct 09, 2005 3:00 pm
Location: Missouri, USA

Postby adjanimals » Wed Nov 01, 2006 9:48 am

OK, So it works in mice, that dosen't help me. Let's get moving to try it in humans or is this another deal where they will need more years of research before it can be tried in humans.
Talk talk talk all talk, how about some action.
User avatar
Family Member
Posts: 93
Joined: Sat Jul 10, 2004 3:00 pm
Location: Minnesota, USA

Return to Drug Pipeline

Who is online

Users browsing this forum: No registered users

Contact us | Terms of Service